Medical Oncology Santa Croce and Carle General Hospital Cuneo, Cuneo, Italy.
Consultant, Candiolo Cancer Institute, FPO-IRCCS Turin, Cuneo, Italy.
Tumori. 2021 Dec;107(6):NP101-NP104. doi: 10.1177/03008916211026971. Epub 2021 Jul 6.
Sinonasal undifferentiated carcinoma (SNUC) is an uncommon aggressive tumor. Locally advanced disease is usually diagnosed at presentation. Multidisciplinary approach is essential and aims to ensure optimal trimodal strategy. Induction chemotherapy is preferred in order to select patients who will benefit from chemoradiotherapy or surgery. Immunotherapy is not indicated in patients with recurrent SNUC. We describe an impressive response in a young man previously treated with radiotherapy and chemotherapy and demolitive surgery who had metastatic bone and lung disease. We also report data on PD-L1, next-generation sequencing, and neutrophil/platelets ratio.
鼻及鼻窦未分化癌(SNUC)是一种罕见的侵袭性肿瘤。局部晚期疾病通常在就诊时被诊断出来。多学科方法是必不可少的,目的是确保最佳的三联疗法。诱导化疗是首选,以选择将从放化疗或手术中受益的患者。对于复发性 SNUC 患者,不建议使用免疫疗法。我们描述了一位年轻患者的显著反应,该患者先前接受过放疗、化疗和破坏性手术治疗,患有转移性骨和肺疾病。我们还报告了 PD-L1、下一代测序和中性粒细胞/血小板比值的数据。